• No results found

Intervention in hepatic lipid metabolism : implications for atherosclerosis progression and regression

N/A
N/A
Protected

Academic year: 2021

Share "Intervention in hepatic lipid metabolism : implications for atherosclerosis progression and regression"

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Intervention in hepatic lipid metabolism : implications for atherosclerosis progression and regression

Li, Z.

Citation

Li, Z. (2011, September 27). Intervention in hepatic lipid metabolism : implications for atherosclerosis progression and regression. Retrieved from

https://hdl.handle.net/1887/17872

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/17872

Note: To cite this publication please use the final published version (if applicable).

(2)

Intervention in Hepatic Lipid Metabolism:

Implications for Atherosclerosis Progression and Regression

PROEFSCHRIFT

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van de Rector Magnificus Prof. Mr. P.F. van der Heijden, volgens besluit van het College voor Promoties

te verdedigen op dinsdag 27 september 2011 klokke 11.15 uur

door

Zhaosha Li

geboren te Changsha, China

in 1983

(3)

PROMOTIECOMMISSIE

Promotor: Prof. Dr. Th.J.C. van Berkel Co-promotor: Dr. M. Hoekstra

Overige leden: Prof.Dr.M.Danhof (LACDR, Leiden University) Prof.Dr.A.IJzerman (LACDR, Leiden University)

Dr.M.Smit (MSD Oss)

Prof.Dr.B. Staels (Université Lille Nord de France)

The studies presented in this thesis were supported by Top Institute Pharma (TI Pharma) project T2-110-1 and were performed at the Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.

(4)

Time will tell.

To my parents

For my love Tristan

(5)

Intervention in Hepatic Lipid Metabolism: Implications for Atherosclerosis Progression and Regression

Author: Zhaosha Li

Lay-out: Zhaosha Li

Cover design: Mai Chen; Zhaosha Li Venetian mask

Print: Wöhrmann Print Service

ISBN: 978-90-8570-855-1

Academic thesis, Leiden University, Leiden, The Netherlands

© Z. Li, Leiden 2011

All rights reserved. No part of this publication may be reproduced, stored, or transmitted in any form or by any means, without permission of the author.

Printing of this thesis was financially supported by:

- LACDR

- Leiden University

(6)

TABLE OF CONTENTS

Page

Chapter 1 General introduction 8

Chapter 2 Gene Expression Profiling of Nuclear Receptors in Mouse Liver Parenchymal, Endothelial, and Kupffer Cells

Submitted for publication

30

Chapter 3 The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status

J Hepatol. 2010;52:244-251

44

Chapter 4 Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice Submitted for publication

60

Chapter 5 Effects of pyrazole partial agonists on HCA2- mediated flushing and hepatic VLDL production in mice

Submitted for publication

74

Chapter 6 LXR activation is essential to induce atherosclerotic plaque regression in C57BL/6 mice

Submitted for publication

88

Chapter 7 Bone marrow reconstitution in ApoE–/– mice: a novel model to induce atherosclerotic plaque regression

104

Chapter 8 General discussion and perspectives 124 Chapter 9 English summary

Nederlandse samenvatting List of abbreviations List of publications Curriculum vitae

134 137 140 142 144

(7)

Referenties

GERELATEERDE DOCUMENTEN

Recently, we showed that niacin also reduces the hepatic expression and plasma levels of the pro- atherogenic cholesteryl ester transfer protein (CETP) in mouse

In contrast to NRs discussed above which were mainly characterized by significantly high expression in either parenchymal or non-parenchymal cells, five NRs were

Combined, these data show that fasting induces a similar response in PNPLA3 expression in fatty liver and white adipose tissue, suggesting that PNPLA3 may have

In the current study, a reduction in the hepatic MCP-1 expression was associated with decreased CD68 and ABCG1 gene expression in liver, and also a reduced number of macrophages

Concomitant with the plasma VLDL-lowering effect, treatment of both LUF compounds resulted in a more than 40% reduction in the expression levels of apolipoprotein

The LXR agonist T0901317 not only reduced plasma (V)LDL-cholesterol levels, but also significantly increased HDL-cholesterol level, leading to a 10-fold increased ratio

reduction with LXR activation. This can be explained by the difference in plaque composition and characteristics between initial and advanced lesion.. contain primarily

mice to restore sustained expression of the LDLr protein in the liver, there was drastic reduction of plasma cholesterol and non-HDL cholesterol levels persistently and